Article information
Abstract
In vitro activity of doripenem and comparator antimicrobial agents was evaluated against Gram-negative bacilli recently isolated from Brazilian private hospitals that were enrolled in the INVITA-A-DORI Brazilian Study. A total of 805 unique Gram-negative bacilli were collected from patients hospitalized at 18 medical centers between May/08 and March/09. Each hospital was asked to submit 50 single Gram-negative bacilli isolated from blood, lower respiratory tract or intraabdominal secretions. Bacterial identification was confirmed and antimicrobial susceptibility testing was performed using Clinical Laboratory Standards Institute (CLSI) microdilution method at a central laboratory. CLSI M100-S21 (2011) or US-FDA package insert criteria (tigecycline) was used for interpretation of the antimicrobial susceptibility results. Doripenem was as active as meropenem and more active than imipenem against E. coli and K. pneumoniae isolates. A total of 50.0% of Enterobacter spp. isolates were resistant to ceftazidime but 85.7% of them were inhibited at doripenem MICs≤1μg/mL. Polymyxin B was the only agent to show potent activity against Acinetobacter spp. (MIC50/90,≤0.5/1μg/mL) and P. aeruginosa (MIC50/90, 1/2μg/mL). Although high rates of imipenem (53.1%) and meropenem (44.5%) resistance were detected among P. aeruginosa, doripenem showed MIC50 of 16μg/mL against imipenem-resistant P. aeruginosa and inhibited a greater number of imipenem-resistant P. aeruginosa (10.5%) at MIC values of≤4μg/mL than did meropenem (0.0%). In this study, doripenem showed similar in vitro activity to that of meropenem and retained some activity against imipenem-resistant P. aeruginosa isolated from Brazilian medical centers.
Keywords:
carbapenems
Gram-negative bacteria
Brazil
Full text is only available in PDF
References
[1.]
G.G. Zhanel, R. Wiebe, L. Dilay, et al.
Comparative review of the carbapenems.
Drugs, 67 (2007), pp. 1027-1052
[2.]
M. Tsuji, Y. Ishii, A. Ohno, S. Miyazaki, K. Yamaguchi.
In vitro and in vivo antibacterial activities of S-4661, a new carbapenem.
Antimicrob Agents Chemother, 42 (1998), pp. 94-99
[3.]
T.A. Davies, W. Shang, K. Bush, R.K. Flamm.
Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.
Antimicrob Agents Chemother, 52 (2008), pp. 1510-1512
[4.]
JNJ-38174942 (Doripenem) NDA 22-171: Advisory Committee Briefing Book. Dopipenem for Injection for the Treatment of Nosocomial Pneumonia. 2008; Johnson & Johnson Pharmaceutical Research & Development. L.L.C. Meeting of Anti-Infective Drugs Advisory Committee.
[5.]
Hanaki H, Kondo N, Inaba Y, Kuwahara K, Asada K. In vitro activity of S-4661, a new 1-beta-methyl carbapenem, against gram-positive and gram-negative bacterial isolates. 1996;36th Intersci. Conf. Antimicrob. Agents Chemother.
[6.]
Sasaki S, Murakami K, Nishitani Y, Kuwahara S. S-4661, a new carbapenem: I. in vitro antibacterial activity. 1994; 34th Intersci. Conf. Antimicrob. Agents Chemother.
[7.]
D.J. Cada, T. Levien, B. Mistry, D.E. Baker.
Doripenem for injection.
Hospital Farmacy, 43 (2008), pp. 210-221
[8.]
Doribax[package insert]. Raritan, NJ: Ortho-McNeil Pharmaceutical, Inc, 2007.
[9.]
H.S. Sader, A.C. Gales.
Treatment of severe infections in the era of high rates of antimicrobial resistance.
Braz J Infect Dis, 12 (2008), pp. 1-2
[10.]
S.S. Andrade, H.S. Sader, A.L. Barth, J. Ribeiro, C. Zoccoli, A.C. Pignatari, A.C. Gales.
Antimicrobial susceptibility patterns of gram-negative bacilli isolated in Brazilian hospitals participating in the SENTRY Program (2003–2008).
Braz J Infect Dis, 12 (2008), pp. 3-9
[11.]
T.C. Horan, M. Andrus, M.A. Dudeck.
Am J Infect Control, 36 (2008), pp. 309-332
[12.]
Clinical and Laboratory Standards Institute (CLSI). M7-A8, Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard - eighth edition. Wayne, PA: CLSI, 2009.
[13.]
Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing: nineteen informational supplement (M100-S21), Wayne, PA: CLSI, 2011.
[14.]
Tygacil [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc, 2005.
[15.]
D.L. Paterson.
Resistance in Gram-negative bacteria: Enterobacteriaceae.
Am J Med, 119 (2006), pp. S20-S28
[16.]
R. Canton, T.M. Coque.
The CTX-M β-lactamase pandemic.
Curr Opin Microbiol, 9 (2006), pp. 466-475
[17.]
J.D. Pitout, P. Nordmann, K.B. Laupland, L. Poirel.
Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community.
J Antimicrob Chemother, 56 (2005), pp. 52-59
[18.]
L.A. Minarini, A.C. Gales, I.C. Palazzo, A.L. Darini.
Prevalence of community-occurring extended spectrum beta-lactamaseproducing Enterobacteriaceae in Brazil.
Curr Microbiol, 54 (2007), pp. 335-341
[19.]
A.C. Gales, R.N. Jones, H.S. Sader, T.R. Fritsche.
Antimicrobial activity of doripenem tested against leading bacterial pathogens: Results from the Latin American Surveillance Study.
Braz J Infect Dis, 12 (2008), pp. 59-66
[20.]
R.N. Jones, H.K. Huynh, D.J. Biedenbach, T.R. Fritsche, H.S. Sader.
Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations.
J Antimicrob Chemother, 54 (2004), pp. 144-154
[21.]
S. Sakyo, H. Tomita, K. Tanimoto, S. Fujimoto, Y. Ike.
Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carbapenem doripenem.
J Antibiot, 59 (2006), pp. 220-228
[22.]
S. Mushtaq, Y. Ge, D.M. Livermore.
Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized β-lactamases.
Antimicrob Agents Chemother, 48 (2004), pp. 1313-1319
[23.]
H.K. Huynh, D.J. Biedenbach, R.N. Jones.
Delayed resistance selection for doripenem when passaging Pseudomonas aeruginosa isolates with doripenem plus an aminoglycoside.
Diagn Microbiol Infect Dis, 55 (2006), pp. 241-243
[24.]
R. Redman, T.M. File Jr..
Safety of intravenous infusion of doripenem.
Clin Infect Dis, 49 (2009), pp. S28-S35
[25.]
P.A. Psathas, A. Kuzmission, K. Ikeda, S. Yasuo.
Stability of doripenem in vitro inrepresentative infusion solutions and infusion bags.
Clin Ther, 30 (2008), pp. 2075-2087
[26.]
S. Mushtaq, Y. Ge, D.M. Livermore.
Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential.
Antimicrob Agents Chemother, 48 (2004), pp. 3086-3092
[27.]
Davies TA, Shang W, Redman R, Bush K, Flamm B. Genotyping of Gram-negative uropathogens isolated pre- and post-treatment from subjects in a doripenem clinical trial for complicated urinary tract infections, 2008. WPCCID, Taipei, Taiwan.
[28.]
A.P. Penteado, M. Castanheira, A.C. Pignatari, T. Guimarães, E.M. Mamizuka, A.C. Gales.
Dissemination of blaIMP-1-carrying integron In86 among Klebsiella pneumonia isolates harboring a new trimethoprim resistance gene dfr23.
Diagn Microbiol Infect Dis, 63 (2009), pp. 87-91
[29.]
J. Monteiro, A.F. Santos, M.D. Asensi, G. Peirano, A.C. Gales.
First report of KPC-2-producing Klebsiella pneumoniae strains in Brazil.
Antimicrob Agents Chemother, 53 (2009), pp. 333-334
[30.]
A.P. Zavascki, C.M. Zoccoli, A.B. Machado, et al.
KPC-2-producing Klebsiella pneumoniae in Brazil: a widespread threat in waiting?.
Int J Infect Dis, 14 (2010), pp. 539-540
[31.]
S.A. Van Wart, D.R. Andes, P.G. Ambrose, S.M. Bhavnani.
Pharmacokinetic-pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients.
Diagn Microbiol Infect Dis, 63 (2009), pp. 409-414
[32.]
A. Louie, A. Bied, C. Fregeau, et al.
Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance.
Antimicrob Agents Chemother, 54 (2010), pp. 2638-2645
[33.]
A.M. Queenan, W. Shang, R. Flamm, K. Bush.
Hydrolysis and inhibition profiles of beta-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem.
Antimicrob Agents Chemother, 54 (2010), pp. 565-569
[34.]
A.C. Gales, L.C. Menezes, S. Silbert, H.S. Sader.
Dissemination in distinct Brazilian regions of an epidemic carbapenem-resistant Pseudomonas aeruginosa producing SPM metallo-beta-lactamase.
J Antimicrob Chemother, 52 (2003), pp. 699-702
[35.]
L. Poirel, P. Nordmann.
Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology.
Clin Microbiol Infect, 12 (2006), pp. 826-836
[36.]
K.E. Schimith Bier, S.O. Luiz, M.C. Scheffer, et al.
Temporal evolution of carbapenem-resistant Acinetobacter baumannii in Curitiba, southern Brazil.
Am J Infect Control, 38 (2010), pp. 308-314
[37.]
M. Castanheira, R.N. Jones, D.M. Livermore.
Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp.
Diagn Microbiol Infect Dis, 63 (2009), pp. 426-433
[38.]
M.H. Kollef, D. Nathwani, S. Merchant, C. Gast, A. Quintana, N. Ketter.
Medical resource utilization among patients with ventilator-associated pneumonia: pooled analysis of randomized studies of doripenem versus comparators.
Crit Care, 14 (2010), pp. R84
[39.]
T. Kongnakorn, M. Mwamburi, S. Merchant, K. Akhras, J.J. Caro, D. Nathwani.
Economic evaluation of doripenem for the treatment of nosocomial pneumonia in the US: discrete event simulation.
Curr Med Res Opin, 26 (2010), pp. 17-24
[40.]
A. Tóth, I. Damjanova, E. Puskás, et al.
Emergence of a colistinresistant KPC-2-producing Klebsiella pneumoniae ST258 clone in Hungary.
Eur J Clin Microbiol Infect Dis, 29 (2010), pp. 765-769
Copyright © 2011. Elsevier Editora Ltda.. All rights reserved
